SRTSSensus Healthcare, Inc.

Financing delays crushed Q2 revenue, but management expects recovery in Q3.

Company secures delayed orders and sees growing international demand, positioning for a stronger second half.

Moby summary of Sensus Healthcare, Inc.'s Q2 2026 earnings call

Sensus Healthcare (NASDAQ:SRTS) reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June. Chairman and Chief Executive Officer Joe Sard

Sensus Healthcare’s fair value estimate has been trimmed from US$6.88 to US$5.75, putting a sharper spotlight on what analysts think the stock is worth today. That shift reflects a mix of optimism and caution, as recent research weighs the SRT-100/Vision platform and 2026 reimbursement changes against execution risk and timing. Read on to see how to interpret these updated targets and what to watch as the story continues to evolve. Stay updated as the Fair Value for Sensus Healthcare shifts...

Sensus Healthcare (NASDAQ:SRTS) said its first quarter of 2026 marked a transition period as new dedicated CPT codes for superficial radiotherapy took effect, while revenue declined from the prior year due largely to the absence of sales to its historically largest customer. Chairman and Chief Exec

Moby summary of Sensus Healthcare, Inc.'s Q1 2026 earnings call

Joining me from Sensus Healthcare, Inc. are Joseph C. Sardano, Chairman and Chief Executive Officer, Michael J. Sardano, President, Chief Commercial Officer and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws.

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

2 Reasons Why Wells Fargo Thinks You Should Buy Google Stock Now